Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Feb 15;24(3):329-39.
doi: 10.1002/sim.1975.

On the Efficiency of Targeted Clinical Trials

Affiliations
Comparative Study

On the Efficiency of Targeted Clinical Trials

A Maitournam et al. Stat Med. .

Abstract

The development of genomics-based technologies is demonstrating that many common diseases are heterogeneous collections of molecularly distinct entities. Molecularly targeted therapeutics is often effective only for some subsets patients with a conventionally defined disease. We consider the problem of design of phase III randomized clinical trials for the evaluation of a molecularly targeted treatment when there is an assay predictive of which patients will be more responsive to the experimental treatment than to the control regimen. We compare the conventional randomized clinical trial design to a design based on randomizing only patients predicted to preferentially benefit from the new treatment. Trial designs are compared based on the required number of randomized patients and the expected number of patients screened for randomization eligibility. Relative efficiency depends upon the distribution of treatment effect across patient subsets, prevalence of the subset of patients who respond preferentially to the experimental treatment, and assay performance.

Similar articles

See all similar articles

Cited by 56 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback